Back to search results

Medical Herbs for COVID-19 Inflammation

This study is looking at whether certain medical herbs can help your body fight the COVID-19 virus. Researchers believe that an over-active immune response (called an "immune-storm" or "cytokine-storm") is what causes organ damage and death in COVID-19, not the virus itself. This study will test different combinations of dietary supplements, including PurInf (I), PurPhl (III), and Inflammation (II) (which are mixtures of various herbs), against standard COVID-19 treatments like remdesivir (Veklury) or monoclonal antibodies. The goal is to see if these herbs can reduce inflammation, help damaged organs recover, and prevent antibodies from harming the body. You may be able to join if you are 10-70 years old and have been diagnosed with COVID-19 in the past 1-20 days. The study aims to enroll 100 participants.

Study design
This is an interventional study with a planned enrollment of 100 participants. The phase of the study is not specified.
What's involved
Not specified in the trial record.
Compensation
Not stated in the trial record.
Follow-up
Researchers will measure organ recovery and inflammation at 3 weeks, and antibody effects at 6 weeks.

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.

NCT04790240

Medical Herbs Inhibit Inflammation Directing T Cells to Kill the COVID-19 Virus (COVID)

Recruiting
PHASE1All AgesInterventionalTreatment
All Natural Medicine Clinic, LLC
~100 participants
Updated 2025-02-19 on ClinicalTrials.gov
What's tested:Inflammation (I)Inflammation (II)Inflammation (III)Standard of care

At a glance

Recruiting sites
1 of 1 listed site is recruiting right now
RecruitingSuspended, closed, or not yet open
What they're measuring
recovering damaged organ
Measured over 3 weeks
+2 more outcomes measured

Conditions

Covid19 Virus Infection

Explore related trials

COVID-19 Infection

Where it's being run

1 sites across 1 states
Maryland1

Study leadership

  • Wanzhu Hou, CMD,MD(CN) · PRINCIPAL_INVESTIGATOR · All Natural Medicine Clinic, LLC

Who to contact

Wanzhu Hou, CMD, MD(CN)
[email protected]
1(301)770-4480
Email the study team

Opens a ready-to-send draft in your own email app — review before sending.

Do you actually qualify for this trial?

Add a private profile and we'll compare every criterion below against your situation — and tell you which ones are met, uncertain, or excluding.

Check eligibility for this trial ~2 min · HIPAA-protected · delete anytime
Eligibility criteria

Inclusion

Individuals diagnosed with COVID-19 virus infection in the past 1-20 days must submit the proved metrics of COVID-19 virus marks positive during the registration;
The age of participants is between 10-70 years old;
The participants are received or not received conventional medication treatment, and continuing the treatment patients, could be enrolled in this clinical study;
This clinical study is not restricted to gender, age, sex, race, and nationality;
The participants must have reports of CBC, C3, C4, IgM, IgG, CD4/CD8, and lungs' images ready before the clinical study;
The Participants must repeat the evaluation experiment during and at the end of the clinical study.
Individuals with a prior COVID-19 virus infection that no longer shows up from COVID-19 testing;
Children who are younger than 10-year-old, cannot control themselves to take the medical herbs on time;
Elders whose age beyond 70-year-old, with severe underline illness;
COVID-19 virus-infected patients who do not feel willing to take medical herbs;
Patients diagnosed with COVID-19 virus infection cannot consistently finish the treatment courses for a specific reason;
Patients diagnosed with COVID-19 virus infection but do not willing to share their information with the public;
Current or past participation within a specified timeframe in another clinical trial, as warranted by this intervention's administration;
Severe patients, when there have insufficient normal cells, can be adjusted, with pre-list diseases life-threatening.

What this trial measures

  • recovering damaged organ3 weeks

    comparing imagen of lungs

  • inhibiting inflammation3 weeks

    comparing C-reactive protein (CRP)

  • preventing the antibody depositing on antigen6 weeks

    measuring complement: C3, C4